Literature DB >> 17630201

Resveratrol induces apoptosis, influences IL-6 and exerts immunomodulatory effect on mouse lymphocytic leukemia both in vitro and in vivo.

Tan Li1, Gui-Xiang Fan, Wei Wang, Tong Li, Yu-Kang Yuan.   

Abstract

Resveratrol, a dietary polyphenol found in grapes, has been proposed to act as a chemopreventive or anti-tumor agent in numerous epidemiologic studies. In this study, we investigate the antitumor and immunomodulation effects of resveratrol on mouse lymphocytic leukemia cells L1210 both in vitro and in vivo. Our finding indicates that resveratrol inhibits proliferation, induces apoptosis, and influences cell cycle of L1210 cells in a dose- and time-dependent manner in vitro. Furthermore, resveratrol can exert a dose-related regulatory effect on both innate and specific immune function to L1210-bearing mice. A normalization of CD4/CD8 ratios is noted as well as an enhancement of lymphocyte proliferation, NK cell activity and anti-SRBC titers. Interleukin-6 cellular content and release are suppressed by resveratrol as well as mRNA expression. In conclusion, the data provide new findings with respect to resveratrol mechanism of action to mouse lymphocytic leukemia.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17630201     DOI: 10.1016/j.intimp.2007.05.008

Source DB:  PubMed          Journal:  Int Immunopharmacol        ISSN: 1567-5769            Impact factor:   4.932


  19 in total

1.  The dual role of sirtuins in cancer.

Authors:  Laia Bosch-Presegué; Alejandro Vaquero
Journal:  Genes Cancer       Date:  2011-06

Review 2.  Resveratrol, sirtuins, and the promise of a DR mimetic.

Authors:  Joseph A Baur
Journal:  Mech Ageing Dev       Date:  2010-02-26       Impact factor: 5.432

3.  An immunological perspective for preventing cancer with berries.

Authors:  Pan Pan; Yi-Wen Huang; Kiyoko Oshima; Martha Yearsley; Jianying Zhang; Jianhua Yu; Mark Arnold; Li-Shu Wang
Journal:  J Berry Res       Date:  2018-08-03       Impact factor: 2.352

4.  Resveratrol, a multitargeted agent, can enhance antitumor activity of gemcitabine in vitro and in orthotopic mouse model of human pancreatic cancer.

Authors:  Kuzhuvelil B Harikumar; Ajaikumar B Kunnumakkara; Gautam Sethi; Parmeswaran Diagaradjane; Preetha Anand; Manoj K Pandey; Juri Gelovani; Sunil Krishnan; Sushovan Guha; Bharat B Aggarwal
Journal:  Int J Cancer       Date:  2010-07-15       Impact factor: 7.396

5.  Role of SIRT1 in Streptococcus pneumoniae-induced human β-defensin-2 and interleukin-8 expression in A549 cell.

Authors:  Li Lin; Shun-hang Wen; Shu-zhen Guo; Xiao-yan Su; Hu-jun Wu; Lei Chong; Hai-lin Zhang; Wei-xi Zhang; Chang-chong Li
Journal:  Mol Cell Biochem       Date:  2014-06-04       Impact factor: 3.396

6.  Impaired DNA damage response, genome instability, and tumorigenesis in SIRT1 mutant mice.

Authors:  Rui-Hong Wang; Kundan Sengupta; Cuiling Li; Hyun-Seok Kim; Liu Cao; Cuiying Xiao; Sangsoo Kim; Xiaoling Xu; Yin Zheng; Beverly Chilton; Rong Jia; Zhi-Ming Zheng; Ettore Appella; Xin Wei Wang; Thomas Ried; Chu-Xia Deng
Journal:  Cancer Cell       Date:  2008-10-07       Impact factor: 31.743

Review 7.  The multiple mechanisms of cell death triggered by resveratrol in lymphoma and leukemia.

Authors:  Raffaele Frazzi; Marco Tigano
Journal:  Int J Mol Sci       Date:  2014-03-20       Impact factor: 5.923

8.  Modulation of Cell Cycle Profile by Chlorella vulgaris Prevents Replicative Senescence of Human Diploid Fibroblasts.

Authors:  Tayyebeh Saberbaghi; Firouz Abbasian; Yasmin Anum Mohd Yusof; Suzana Makpol
Journal:  Evid Based Complement Alternat Med       Date:  2013-03-12       Impact factor: 2.629

9.  Rhamnogalacturonan II is a Toll-like receptor 4 agonist that inhibits tumor growth by activating dendritic cell-mediated CD8+ T cells.

Authors:  Sung Nam Park; Kyung Tae Noh; Young-Il Jeong; In Duk Jung; Hyun Kyu Kang; Gil Sun Cha; Su Jung Lee; Jong Keun Seo; Dae Hwan Kang; Tae-Ho Hwang; Eun Kyung Lee; Byungsuk Kwon; Yeong-Min Park
Journal:  Exp Mol Med       Date:  2013-02-08       Impact factor: 8.718

10.  The Role of Th17 in Neuroimmune Disorders: A Target for CAM Therapy. Part III.

Authors:  Aristo Vojdani; Jama Lambert; Gottfried Kellermann
Journal:  Evid Based Complement Alternat Med       Date:  2011-06-16       Impact factor: 2.629

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.